Nurix Therapeutics (NRIX) Earnings Date & Reports

Key Takeaways

• Nurix Therapeutics reported fiscal second quarter 2026 revenue of $9.0 million, down sharply from $44.1 million in the same quarter last year, as the prior-year period benefited from a one-time $30 million Sanofi license extension.
• Net loss widened to $89.5 million, or ($0.81) per share, missing the consensus analyst estimate of ($0.73) per share by $0.08. Revenue also fell well short of the $15.29 million Wall Street had projected.
• The quarter was defined not by the earnings miss but by the announcement of a landmark global collaboration with Roche for bexobrutideg, Nurix's lead Bruton's tyrosine kinase (BTK) degrader, with potential total payments of up to $2.3 billion including a $700 million upfront payment.
• Cash, cash equivalents, and marketable securities stood at $443.5 million as of May 31, 2026, with pro-forma cash of approximately $1.14 billion when including the expected Roche upfront payment — extending the company's operational runway significantly.
• Research and development (R&D) expenses rose to $87.7 million from $78.1 million a year ago, reflecting accelerated clinical investment ahead of pivotal Phase 3 trials for bexobrutideg in chronic lymphocytic leukemia (CLL).
• Wall Street analysts maintained an overwhelmingly positive stance, with a consensus "Moderate Buy" rating and an average price target of approximately $34.08, signaling that the Roche partnership outweighs near-term financial metrics.

Earnings Context and Why It Matters

For a clinical-stage biopharmaceutical company like Nurix Therapeutics, quarterly earnings carry a different weight than they do for commercial-stage enterprises. Revenue is driven almost entirely by collaboration agreements, not product sales, and bottom-line losses are expected as the company invests heavily in advancing its pipeline of targeted protein degradation medicines. What made this particular report critical was the convergence of two narratives: a wider-than-expected quarterly loss and the transformative Roche deal. Investors were less focused on the headline EPS miss and far more attuned to the long-term implications of securing a global partner with the resources to accelerate bexobrutideg across multiple indications — including malignant hematology, immunology, and neurology.

Reported Results

Nurix Therapeutics reported total revenue of $9.0 million for the fiscal second quarter ended May 31, 2026, a steep decline from $44.1 million in the same period a year earlier. The year-over-year drop was largely mechanical: the prior-year quarter included $30 million in license revenue from two Sanofi license extensions, a non-recurring item that inflated the 2025 figure. Collaboration revenue in the current quarter included a $2 million research milestone achieved under the Sanofi partnership.

Research and development expenses climbed to $87.7 million, up from $78.1 million in the second quarter of fiscal 2025, driven by increased clinical trial and contract manufacturing costs as the company enrolled patients in the Phase 2 trial of bexobrutideg and prepared for pivotal Phase 3 studies. General and administrative (G&A) expenses rose to $15.6 million from $14.3 million, primarily due to legal costs tied to collaboration and business development activities, including the Roche transaction.

The net loss for the quarter reached $89.5 million, or ($0.81) per share, compared to a net loss of $43.5 million, or ($0.52) per share, in the prior-year period. Analyst consensus had projected a loss of ($0.73) per share on revenue of $15.29 million, meaning Nurix missed on both top- and bottom-line estimates. For the first six months of fiscal 2026, total revenue was $15.3 million and the net loss was $176.7 million, or ($1.60) per share.

As of May 31, 2026, the company held $443.5 million in cash, cash equivalents, and marketable securities, down from $592.9 million at the end of fiscal 2025. However, pro-forma cash is approximately $1.14 billion when including the expected $700 million upfront payment from Roche, which the company anticipates receiving in the third fiscal quarter of 2026.

AI Screener

For investors seeking to identify opportunities across the biotechnology sector or any other industry, Tickeron's AI Screener offers a powerful, AI-driven discovery tool that scans thousands of stocks and ETFs using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. Whether tracking earnings momentum, breakout candidates, or stocks exhibiting specific technical formations, the AI Screener helps traders and investors cut through market noise and surface trade ideas more efficiently than manual screening methods. Explore the platform to see how AI-powered filtering can complement your research workflow.

Market Reaction and Investor Sentiment

Shares of Nurix Therapeutics closed at $24.69 on the day of the earnings release, up 1.56%, indicating that the market chose to reward the Roche collaboration news rather than penalize the earnings miss. The stock has traded in a 52-week range of $8.19 to $25.08. The post-earnings analyst response was decisively bullish: firms including Needham, Truist, Mizuho, and HC Wainwright reiterated Buy or Outperform ratings, with price targets ranging from $33 to $34. The consensus view among analysts is that the Roche partnership de-risks the bexobrutideg program, provides non-dilutive capital at a critical juncture, and validates Nurix's targeted protein degradation platform in the eyes of a major pharmaceutical partner. The revenue and EPS shortfalls, while notable, were largely dismissed as transient, explained by the absence of the prior year's one-time license fees and the natural lumpiness of collaboration-driven revenue recognition in biotech.

Forward Outlook and Key Factors to Monitor

Looking ahead, the single most consequential near-term catalyst for Nurix Therapeutics is the closing of the Roche collaboration and the receipt of the $700 million upfront payment, expected in the fiscal third quarter of 2026. That infusion will transform the company's balance sheet and, by management's assessment, fund operations for at least the next 12 months.

Beyond the capital raise, investors should closely track the initiation of pivotal Phase 3 trials for bexobrutideg in chronic lymphocytic leukemia (CLL), which the company has signaled are on track to begin. The Roche deal also opens the door for clinical expansion into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS), two large-market indications that could materially broaden the drug's commercial opportunity — but also add complexity and cost to the development timeline.

Pipeline diversification remains another critical theme. Beyond bexobrutideg, Nurix continues to advance zelebrudomide (NX-2127), its second BTK degrader, and NX-1607, an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates immune cell activation. Progress updates on these programs, along with milestone achievements under existing collaborations with Sanofi, Gilead, and Pfizer, will help shape the investment narrative between now and year-end.

On the cost side, R&D expenses are likely to continue rising as clinical programs advance into later-stage trials. While the Roche partnership alleviates immediate financing concerns, investors should remain aware that Nurix will eventually need substantial additional funding to support long-term commercialization — and that operating losses are expected to persist until the company generates meaningful product revenue, which remains years away.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations